<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321111</url>
  </required_header>
  <id_info>
    <org_study_id>HSC20140497H</org_study_id>
    <nct_id>NCT02321111</nct_id>
  </id_info>
  <brief_title>The Role of TLR4 on Lipid-induced Insulin Resistance</brief_title>
  <acronym>Eritoran1</acronym>
  <official_title>The Role of TLR4 on Lipid-Induced Insulin Resistance</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Texas Health Science Center at San Antonio</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Texas Health Science Center at San Antonio</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether pharmacologic inhibition of Toll-like
      receptor 4 (TLR4) with eritoran for injection (E5564) prevents lipid-induced insulin
      resistance in lean, normal glucose tolerant (NGT) subjects.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      E5564 = Eritoran
    </textblock>
  </detailed_description>
  <overall_status>Suspended</overall_status>
  <why_stopped>
    Study drug expired, pending receipt of drug availability from supplier.
  </why_stopped>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">October 2018</completion_date>
  <primary_completion_date type="Anticipated">October 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Participant, Care Provider, Investigator, Outcomes Assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of Eritoran on muscle insulin action</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
    <description>Muscle insulin action = Insulin signaling and glucose disposal in muscle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effect of Eritoran on hepatic insulin sensitivity</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
    <description>Hepatic insulin sensitivity = What insulin suppression of endogenous glucose production is</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on Inflammatory signaling in muscle</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on TLR4 expression on peripheral blood monocytes</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on Plasma cytokine concentration</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Eritoran on Intramyocellular diacylglycerol and ceramide content</measure>
    <time_frame>within 107 days (plus or minus 10 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Insulin Sensitivity</condition>
  <arm_group>
    <arm_group_label>D5W (5% Dextrose in water) + Saline</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV administration of 5% Dextrose in water/D5W (vehicle) 12 mg every 12 hours plus Saline infusion at a rate of 30 mL/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>D5W (5% Dextrose in water) + Intralipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV Administration of 5% Dextrose in water /D5W (vehicle) 12 mg plus Intralipid infusion at a rate of 30 ml/hour</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eritoran + Intralipid</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>IV administration of Eritoran 12 mg every 12 hours plus Intralipid infusion at a rate of 30 ml/hour</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eritoran</intervention_name>
    <description>Eritoran = E5564 Eritoran is a pharmacologic inhibitor of TLR4.</description>
    <arm_group_label>Eritoran + Intralipid</arm_group_label>
    <other_name>E5564</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>D5W (5% Dextrose in water)</intervention_name>
    <description>D5W = 5% Dextrose Water Vehicle</description>
    <arm_group_label>D5W (5% Dextrose in water) + Saline</arm_group_label>
    <arm_group_label>D5W (5% Dextrose in water) + Intralipid</arm_group_label>
    <other_name>Vehicle</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects capable of giving informed consent.

          -  lean (BMI &lt;26 kg/m2)

          -  normal glucose-tolerant subjects (completers) without a family history of Type 2
             diabetes mellitus (DM)

          -  Both genders. (50% males)

          -  Age = 18-65 years. Older subjects are excluded because aging is a pro-inflammatory
             state.

          -  All ethnic groups

          -  Premenopausal women in the follicular phase, non-lactating, and with a negative
             pregnancy test. Postmenopausal women on stable dose of or not exposed to hormone
             replacement for &gt;=6 months.

          -  Lab: Hematocrit &gt;=34%, serum creatinine &lt;=1.4 mg/dL, normal electrolytes, urinalysis,
             and coagulation tests. Liver function tests up to 2x normal range.

          -  Stable body weight (+/-1%) for &gt;=3 months.

          -  One or less sessions of strenuous exercise/wk for last 6 months.

        Exclusion Criteria:

          -  Presence of diabetes or impaired glucose tolerance based on ADA criteria;

          -  Current treatment with drugs known to affect glucose and lipid homeostasis. Subjects
             on a stable dose of statin (&gt;3months) are eligible.

          -  Non-steroidal anti-inflammatory drugs or systemic steroid use for more than 1 week
             within 3 months.

          -  Current treatment with anticoagulants (warfarin). Aspirin (up to 325 mg) and
             clopidogrel will be permitted if these can be held for seven days prior to the
             biopsies.

          -  History of heart disease (New York Heart Classification greater than class II; more
             than non-specific ST-T wave changes on the ECG), peripheral vascular disease,
             pulmonary disease, smokers.

          -  Poorly controlled blood pressure (systolic BP&gt;160, diastolic BP&gt;90 mmHg).

          -  Active inflammatory, autoimmune, infectious, hepatic, gastrointestinal, malignant, and
             psychiatric disease.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nicolas Musi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>The University of Texas Health Science Center at San Antonio</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Audie L. Murphy VA Hospital, STVHCS</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 29, 2014</study_first_submitted>
  <study_first_submitted_qc>December 19, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 22, 2014</study_first_posted>
  <last_update_submitted>September 6, 2017</last_update_submitted>
  <last_update_submitted_qc>September 6, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 11, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>The University of Texas Health Science Center at San Antonio</investigator_affiliation>
    <investigator_full_name>Nicolas Musi</investigator_full_name>
    <investigator_title>Nicolas Musi, MD</investigator_title>
  </responsible_party>
  <keyword>Insulin signaling and glucose disposal in muscle</keyword>
  <keyword>Hepatic insulin sensitivity</keyword>
  <keyword>TLR4 signaling and inflammatory gene expression</keyword>
  <keyword>Plasma cytokine concentration</keyword>
  <keyword>Intramyocellular diacylglycerol and ceramide content</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypersensitivity</mesh_term>
    <mesh_term>Insulin Resistance</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin, Globin Zinc</mesh_term>
    <mesh_term>Insulin</mesh_term>
    <mesh_term>Soybean oil, phospholipid emulsion</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

